What are the side effects of Riboxil/Calilon?

As a member of CDK4/6 inhibitors, Ribociclib/Calilon(Ribociclib) has demonstrated significant disease control advantages in the treatment of breast cancer, but patients will inevitably face side effects during the medication. Understanding the possible adverse reactions will not only help patients improve compliance, but also help doctors conduct more scientific monitoring and intervention during the management process.

The most common side effects are hematological problems, especially neutropenia. This is a typical feature of CDK4/6 inhibitors, which manifests as a decrease in the patient's blood count, thereby increasing the risk of infection. In most cases, this side effect is reversible and usually improves with dose adjustment or temporary discontinuation, so regular hematological monitoring is important.

In addition to hematological adverse reactions, ribociclib may also affect liver function. In clinical practice, some patients will experience elevated transaminases or abnormal liver function indicators. Therefore, it is recommended to regularly check liver function indicators during medication so that timely detection and measures can be taken. At the same time, the drug may also affect the electrical activity of the heart, especially prolonging the QT interval. This is a risk point that doctors pay special attention to when prescribing. It is usually necessary to cooperate with electrocardiogram monitoring to reduce potential risks.

Among non-hematological side effects, patients may experience fatigue, weakness, decreased appetite, and some may experience mild nausea or gastrointestinal discomfort. Most of these symptoms are controllable and can be alleviated by adjusting diet or taking auxiliary medications. Some patients may also experience skin rash, mild hair loss, or weight changes. These conditions usually do not cause treatment interruption, but communication with the doctor is still required for a comprehensive evaluation.

It is worth emphasizing that the occurrence of side effects does not mean that the drug cannot be continued. The treatment concept of Riboxiclib is long-term management, so doctors will flexibly adjust the dosage according to the patient's actual condition rather than discontinuing the drug completely simply because of side effects. Compared with traditional chemotherapy, the toxic and side effects of ribociclib are more controllable and reversible. Patients can often balance efficacy and safety through regular follow-up, monitoring indicators and improving lifestyle.

Reference materials:https://us.kisqali.com/